0OO9 Stock Overview
Fresenius SE & Co. KGaA, una empresa de asistencia sanitaria, ofrece productos y servicios para pacientes con enfermedades crónicas.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Fresenius SE & Co. KGaA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €25.44 |
| 52 Week High | €31.23 |
| 52 Week Low | €23.94 |
| Beta | 1.08 |
| 1 Month Change | -1.07% |
| 3 Month Change | -10.20% |
| 1 Year Change | -0.059% |
| 3 Year Change | -34.36% |
| 5 Year Change | -50.16% |
| Change since IPO | 38.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0OO9 | GB Healthcare | GB Market | |
|---|---|---|---|
| 7D | 1.7% | -1.1% | -0.5% |
| 1Y | -0.06% | -23.7% | 0.4% |
Rentabilidad frente al sector: 0OO9 superó al sector UK Healthcare , que obtuvo un rendimiento del -11.7% el año pasado.
Rentabilidad vs. Mercado: 0OO9 igualó al mercado UK, que obtuvo un rendimiento del 0.4% el año pasado.
Price Volatility
| 0OO9 volatility | |
|---|---|
| 0OO9 Average Weekly Movement | 3.5% |
| Healthcare Industry Average Movement | 7.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Precio estable de las acciones: 0OO9 no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de 0OO9 (3%) se ha mantenido estable durante el año pasado.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1912 | 193,865 | Michael Sen | https://www.fresenius.com |
Fresenius SE & Co. KGaA, una empresa de asistencia sanitaria, ofrece productos y servicios para pacientes con enfermedades crónicas. Opera a través de cuatro segmentos: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios y Fresenius Vamed. El segmento Fresenius Medical Care ofrece productos y servicios para pacientes con insuficiencia renal crónica.
Fresenius SE & Co. KGaA Fundamentals Summary
| 0OO9 fundamental statistics | |
|---|---|
| Market cap | €14.44b |
| Earnings (TTM) | €353.00m |
| Revenue (TTM) | €22.30b |
40.9x
P/E Ratio0.6x
P/S RatioIs 0OO9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0OO9 income statement (TTM) | |
|---|---|
| Revenue | €22.30b |
| Cost of Revenue | €17.24b |
| Gross Profit | €5.06b |
| Other Expenses | €4.71b |
| Earnings | €353.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 08, 2024
| Earnings per share (EPS) | 0.63 |
| Gross Margin | 22.68% |
| Net Profit Margin | 1.58% |
| Debt/Equity Ratio | 70.4% |
How did 0OO9 perform over the long term?
See historical performance and comparison